GT200100079A - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
GT200100079A
GT200100079A GT200100079A GT200100079A GT200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A
Authority
GT
Guatemala
Prior art keywords
ryk
disease
protein
regulating angiogenesis
angiogenesis
Prior art date
Application number
GT200100079A
Other languages
English (en)
Spanish (es)
Inventor
Steve Rockzniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100079A publication Critical patent/GT200100079A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GT200100079A 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk GT200100079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
GT200100079A true GT200100079A (es) 2001-12-31

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100079A GT200100079A (es) 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (enExample)
JP (1) JP2004527206A (enExample)
AR (1) AR028424A1 (enExample)
AU (1) AU2001261343A1 (enExample)
CA (1) CA2408349A1 (enExample)
CO (1) CO5300464A1 (enExample)
DO (1) DOP2001000164A (enExample)
EC (1) ECSP014068A (enExample)
GT (1) GT200100079A (enExample)
PE (1) PE20011218A1 (enExample)
SV (1) SV2002000442A (enExample)
UY (1) UY26696A1 (enExample)
WO (1) WO2001085789A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516608A (ja) * 2002-02-06 2005-06-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング エネルギー恒常性の調節に関与するキナーゼ
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶(ryk)抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107472A (en) * 1992-05-11 2000-08-22 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
EP1084245B1 (en) * 1998-06-11 2006-03-29 AstraZeneca AB Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
PE20011218A1 (es) 2002-02-01
SV2002000442A (es) 2002-07-03
CA2408349A1 (en) 2001-11-15
EP1287121A2 (en) 2003-03-05
AU2001261343A1 (en) 2001-11-20
ECSP014068A (es) 2002-02-25
UY26696A1 (es) 2001-12-28
DOP2001000164A (es) 2002-05-15
WO2001085789A2 (en) 2001-11-15
AR028424A1 (es) 2003-05-07
JP2004527206A (ja) 2004-09-09
WO2001085789A3 (en) 2002-05-16
CO5300464A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
AR030631A1 (es) Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
ES2157422T3 (es) Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
MX2024005705A (es) Composiciones de liquidos ionicos.
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
BR0206549A (pt) Uso de flumazenil na produção de uma droga para o tratamento de dependência de álcool
GT200100079A (es) Metodo para regular la angiogenesis utilizando proteina ryk
DK1343472T3 (da) Thixotropisk næsespray
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
HN1998000141A (es) Composicion farmaceutica antimastitica a base de extractos de origen natural y procedimientom para fabricarla.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.